An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma

Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). This phase 1b study (NCT02048384) was conducted to evaluate the feasibility and activity of metformin +/– rapamycin in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bever, Katherine M., Borazanci, Erkut H., Thompson, Elizabeth A., Durham, Jennifer N., Pinero, Kimberly, Jameson, Gayle S., Vrana, Amber, Liu, Meizheng, Wilt, Cara, Wu, Annie A., Fu, Wei, Wang, Hao, Yin, Yafu, Leal, Jeffrey P., Jesus-Acosta, Ana De, Zheng, Lei, Laheru, Daniel A., Von Hoff, Daniel D., Jaffee, Elizabeth M., Powell, Jonathan D., Le, Dung T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260120/
https://www.ncbi.nlm.nih.gov/pubmed/32523648
http://dx.doi.org/10.18632/oncotarget.27586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260120/
https://www.ncbi.nlm.nih.gov/pubmed/32523648
http://dx.doi.org/10.18632/oncotarget.27586

Ejemplares similares